Global Intravenous (IV) Iron Drugs Market, 2024 - Increasing Trend towards Bundled Reimbursements

DUBLIN, October 23, 2017 /PRNewswire/ --

The "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report has been added to Research and Markets' offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

The report profiles 21 companies including many key and niche players such as:

• Allergan Plc. (Ireland)
• AMAG Pharmaceuticals, Inc. (USA)
• Daiichi Sankyo, Inc. (USA)
• Luitpold Pharmaceuticals, Inc. (USA)
• American Regent, Inc. (USA)
• Pharmacosmos A/S (Denmark)
• Sanofi US (USA)
• Vifor Pharma Ltd. (Switzerland)
• Vifor Fresenius Medical Care Renal Pharma (Switzerland)

Key Topics Covered:

1. GLOBAL MARKET OVERVIEW
Iron Deficiency Anemia (IDA)
An Overview
Intravenous (IV) Iron Drugs Market
A Quick Primer
US and Europe Dominate IV Iron Market
Asia-Pacific
The Fastest Growing Market
Leading Intravenous Iron Drugs Globally
Leading IV Iron Drugs Available in the Market
Leading Intravenous Iron Drugs: In a Nutshell
Ferinject/Injectafer
The Leading Intravenous Iron Drug Globally
Venofer
Looses Ground to Ferinject
Feraheme Obtains Broader Label Approval
Feraheme Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA
Gluconate (Ferrlecit and Nulecit)
Dextran
Global Market Leaders

2. GROWTH DRIVERS & MARKET TRENDS
Expanding Pool of ESRD and CKD Patients
The Major Growth Driver for Intravenous (IV) Iron Drugs
ESRD Prevalence Statistics: An Opportunity Indicator
Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
Dialysis Patients
A Major Market for Intravenous Iron Supplements
Ageing Population Drives Demand for IV Iron Drugs
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure
A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements
Correction of IDA in Pregnancy Signals Opportunities
Women's Health
A Key Growth Opportunity
Perioperative and Postoperative Anemia
A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW
Increasing Trend towards Bundled Reimbursements
A Glimpse of Regulations in the US and Europe
Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS
Iron
A Vital Element
Iron-Deficiency Anemia
Intravenous Therapy
Patients of Chronic Illnesses, the Elderly and Women
The High Risk Population
Treatment for Iron Deficiency Anemia
Iron Requirement in Chronic Kidney Disease
Classification of Iron Deficiency in CKD
Treating Iron Deficiency in CKD Patients
Side Effects of Iron Supplementation in CKD
Methods of Restoring Iron
Oral Iron Therapy
IV Iron-Infusion Therapy
Intravenous (IV) Iron
Conditions for Receiving Iron Injections
Injection Procedure
Categories of Iron Injections
Suitability of IV Iron Preparation
Suitability of Regimen
Management of Iron Doses
Effectiveness of Iron Injection
Requirement of Test Dose
Adverse Effects of Iron Injections
Iron Therapy: Caution
Duration of Iron Infusion
Iron Overdose
Iron-Out-of-Balance Therapies
Blood Donation
Therapeutic Phlebotomy
Red Cell Apheresis
Iron Chelation Therapy
Iron-Chelating Drugs
Desferrioxamine or Desferal
Deferiprone or Ferriprox
Conditions for Undergoing Iron Chelation Therapy
Kinds of Chelation Therapy
Side Effects Caused by IV Iron Chelation

5. RECENT INDUSTRY ACTIVITY
AMAG to Expand Feraheme Label
Pharmacosmos and Laboratoire Aguettant to Commercialize Monover in France
Pharmacosmos and Pfizer to Commercialize Monover in Brazil
Rockwell Medical Announces Data Presentation on Triferic Intravenous (IV) Administration
Nippon Shinyaku and Pharmacosmos to Develop and commercialize Monofer in Japan
Lupin Announces the Launch of Novel Injectable Iron Formulation in India
Pharmacosmos and Pfizer to Commercialize Monofer in Canada

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 21 (including Divisions/Subsidiaries 22)

• The United States (5)
• Japan (2)
• Europe (7)
• France (1)
• Germany (1)
• The United Kingdom (1)
• Rest of Europe (4)
• Asia-Pacific (Excluding Japan) (8)

For more information about this report visit https://www.researchandmarkets.com/research/88ct5n/intravenous_iv

Media Contact:

Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]